Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$39 Mln
Revenue (TTM)
$-118 Mln
Net Profit (TTM)
$0 Mln
ROE
-10.2 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
53.8
Industry P/E
--
EV/EBITDA
-0.2
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$52.2
Face value
--
Shares outstanding
4,045,445
CFO
$-672.00 Mln
EBITDA
$-1,430.64 Mln
Net Profit
$-1,556.34 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
FibroGen (FGEN)
| -14.6 | -18.1 | -31.8 | -35.2 | -77.0 | -64.1 | -33.4 |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
FibroGen (FGEN)
| -33.7 | -40.0 | -94.5 | 13.6 | -62.0 | -13.5 | -7.3 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
FibroGen (FGEN)
|
7.5 | 39.3 | -118.1 | 215.7 | 109.1 | -- | -- | 53.8 |
| 61.0 | 8,546.2 | 1,091.0 | 202.3 | 31.6 | 31.3 | 38.1 | 15.0 | |
| 229.3 | 14,074.4 | 691.7 | -219.0 | -13.7 | 163.2 | -- | 14.6 | |
| 66.7 | 8,218.7 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.5 | |
| 43.9 | 11,247.3 | 2,320.1 | 782.6 | 39.0 | 35.5 | 14.9 | 5.0 | |
| 93.8 | 12,307.7 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 60.9 | |
| 546.9 | 11,592.5 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 16.8 | |
| 498.3 | 14,143.5 | 2,530.2 | 451.1 | 21.3 | 70.2 | 32.7 | 30.2 | |
| 105.4 | 8,288.6 | 0.0 | -425.4 | -- | -36.7 | -- | 6.7 | |
| 310.4 | 8,644.3 | 0.0 | -303.3 | -- | -45.8 | -- | 10.1 |
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl... hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. Its pipeline products include FG-3165 and FG-3175, an anti-GAL-9 antibody for treatment of solid tumors. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California. Read more
CEO & Director
Mr. Thane Wettig
CEO & Director
Mr. Thane Wettig
Headquarters
San Francisco, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of FibroGen Inc (FGEN) is $7.50 (NASDAQ) as of 05-Feb-2026 09:30 EDT. FibroGen Inc (FGEN) has given a return of -76.97% in the last 3 years.
Since, TTM earnings of FibroGen Inc (FGEN) is negative, P/E ratio is not available.
The P/B ratio of FibroGen Inc (FGEN) is 53.83 times as on 05-Feb-2026, a 1253 premium to its peers’ median range of 3.98 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2024
|
-0.04
|
-0.01
|
|
2023
|
-0.31
|
-0.43
|
|
2022
|
-5.13
|
-70.24
|
|
2021
|
-4.49
|
6.25
|
|
2020
|
-17.86
|
8.01
|
The 52-week high and low of FibroGen Inc (FGEN) are Rs 21.94 and Rs 4.85 as of 05-Apr-2026.
FibroGen Inc (FGEN) has a market capitalisation of $ 39 Mln as on 05-Feb-2026. As per SEBI classification, it is a Small Cap company.
Before investing in FibroGen Inc (FGEN), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$-1.72
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.